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Late stage AIDS associated CCR5 tropic HIV-1 clones (R5-AIDS HIV-1) exhibit greater cytopathic effects (CPE) than earlier isolates from the
same patients. In this study, envelopes from a series of three biological clones derived from the same patient were evaluated as a cytopathic
determinant of R5-AIDS HIV-1 for thymocytes. In a single round of replication in thymocytes, the AIDS associated clone mediated greater
initiation of reverse transcription. This enhancement was not due to broadened coreceptor tropism, as all clones studied were exclusively R5
tropic. The full-length R5-AIDS env mediated greater infectivity than R5 pre-AIDS env when used to pseudotype a reporter virus. R5-AIDS env
pseudotypes were more resistant to TAK-779 and showed more rapid infection kinetics but similar resistance to a CD4 blocking mAb. We
conclude that the enhanced thymic replication and CPE shown by the R5-AIDS clone is due to enhanced efficiency of Env-mediated entry via
CCR5.
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HIV-1 infection of humans is characterized by the progres-
sive loss of CD4+ Tcells accompanied by a progressive increase
in the virulence of HIV-1. This increase in HIV-1 virulence
during the course of infection has been repeatedly demonstrated
by an increase in viral replication and cytopathic effects (CPE)
in tissue culture systems (Blaak et al., 1998; Kwa et al., 2003;
Cheng-Mayer et al., 1988; Connor et al., 1993, 1997; Scoggins
et al., 2000). It has long been known that an important reason
for greater CPE of late stage HIV-1 isolates is a switch from
entry via CCR5 to entry via CXCR4 (Camerini et al., 2000;
Connor et al., 1997; Grivel et al., 2000; Jamieson et al., 1995,
1997; Kaneshima et al., 1994; Kwa et al., 2003; Maas et al.,
2000; Penn et al., 1999).
HIV-1 requires CD4 as a receptor, but any of several
chemokine receptors can be used as a coreceptor (Alkhatib et
al., 1997, 1996; Choe et al., 1998, 1996; Deng et al., 1996;⁎ Corresponding author. Fax: +1 949 824 8551.
E-mail address: dcamerin@uci.edu (D. Camerini).
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doi:10.1016/j.virol.2006.08.027Farzan et al., 1997; Feng et al., 1996; Frade et al., 1997; Gallo et
al., 2003; Horuk et al., 1998; Liao et al., 1997; Owman et al.,
1998; Pleskoff et al., 1997; Rucker et al., 1997). However, the
most commonly used coreceptors are CCR5 and CXCR4
(Albright et al., 1999; Bazan et al., 1998; Rucker et al., 1997;
Sheppard et al., 2002; Zhang and Moore, 1999; Zhang et al.,
1998a, 1998b). CCR5 dependent viruses (R5 HIV-1) predomi-
nate during the initial stages of infection and are responsible for
most transmission of HIV-1 (Dean et al., 1996; Liu et al., 1996;
Pillai et al., 2005; Samson et al., 1996). In approximately 50%
of infected individuals, CXCR4 competent viruses, R5X4 or X4
HIV-1, appear, typically late in the course of disease, but some
X4 isolates can appear soon after sero-conversion. These
isolates, however, are not frequently transmitted. In a small
fraction of cases, HIV-1 switches coreceptor tropism to include
one of several other chemokine receptors. In the remaining
cases, HIV-1 retains exclusive CCR5 tropism.
The switch to CXCR4 usage has been shown to correlate
with a more rapid progression to AIDS (Maas et al., 2000;
Richman and Bozzette, 1994; Schuitemaker et al., 1992). The
greater expression of CXCR4 on naive T cells (Bleul et al.,
24 K. Olivieri et al. / Virology 358 (2007) 23–381997; Ostrowski et al., 1998; van Rij et al., 2003) and
thymocytes (Kitchen and Zack, 1999; Taylor et al., 2001;
Zaitseva et al., 1998) is one possible explanation for the ability
of X4 HIV-1 to more rapidly deplete CD4+ T cells. In contrast,
the mechanisms by which R5 HIV-1 causes AIDS are more
poorly defined. Several studies have attempted to elucidate the
changes that occur between pre-AIDS and AIDS associated R5
HIV-1 (Gray et al., 2005; Koning et al., 2003; Scoggins et al.,
2000; van't Wout et al., 1998). It has been shown that R5 tropic
HIV-1 clones, from after the onset of AIDS, cause more
cytopathic effects and are better able to replicate than earlier
isolates (Scoggins et al., 2000; van't Wout et al., 1998). Several
studies have shown that AIDS R5 isolates show a higher
resistance to agents which prevent Env mediated fusion when
compared to R5 pre-AIDS isolates (Gray et al., 2005; Jansson et
al., 1999; Koning et al., 2003; Scarlatti et al., 1997). These
studies indicate that factors influencing viral entry are important
differences between AIDS and pre-AIDS R5 HIV-1 clones.
The HIV-1 env gene is the primary viral determinant of entry.
The env gene product, gp160, is cleaved by a cellular protease
into the gp120 surface subunit (SU) and the gp41 transmem-
brane subunit (TM) (Hallenberger et al., 1992; Stein and
Engleman, 1990; Willey et al., 1988). These glycoproteins,
collectively abbreviated Env, exist in a stable trimeric complex,
with gp41 transversing the viral membrane and gp120 non-
covalently associated with the exterior face of gp41 (Center et
al., 2002; Chertova et al., 2002; Yang et al., 2003; York and
Nunberg, 2004). Gp120 uses highly conserved regions, called
constant regions, to interact with CD4 and form the stable core
of trimeric gp120 (Kwong et al., 1998, 2000; Myszka et al.,
2000). Five variable disulfide bonded loops are external to the
gp120 core. These variable regions and the glycosylation that
occurs there, serve both to protect the core structure from
antibody-mediated neutralization and to govern coreceptor
interactions (Basmaciogullari et al., 2002; Kolchinsky et al.,
2001; Walter et al., 2005; Wyatt et al., 1998; Yang et al., 2004;
Zhang et al., 2002; Zwick et al., 2003).
The gp120/CD4/coreceptor interaction can be studied
kinetically as three different reactions. Initially, gp120 binds
to CD4, creating the CD4/gp120 complex, which triggers gp120
to undergo conformational changes exposing the CCR5 binding
regions (Dimitrov et al., 2001; Doranz et al., 1999; Kwong et
al., 1998; Trkola et al., 1996). The next reaction is the gp120/
CD4 complex binding to CCR5, in a manner dependent on the
sulfation of extracellular tyrosines in the amino terminal domain
of CCR5 (Farzan et al., 1999, 2000; Platt et al., 2005). This
forms the gp120/CD4/CCR5 complex and allows the gp41
fusion peptide to insert into the host cell membrane. Following
this event, each of the N-terminal heptad repeat regions of gp41
folds back on the C-terminal heptad repeats in gp41, forming a
stable trimeric coiled-coil structure or six-helix bundle (Furuta
et al., 1998; Weng and Weiss, 1998). This reaction may disorder
the membranes (Dimitrov et al., 2001) and bring them into close
apposition, allowing fusion of the viral lipid envelope with the
cytoplasmic membrane (Sackett and Shai, 2002; Weissenhorn et
al., 1997). Each of these events can be blocked with monoclonal
antibodies, receptor antagonists or peptide mimics. In this studywe used the CD4 monoclonal antibody B4 to block formation of
the CD4/gp120 complex (Wang et al., 1999), the small
molecule CCR5 antagonist TAK-779 to block the gp120/CD4
complex from binding CCR5 (Baba et al., 1999) and the peptide
T-20 to prevent gp41 function (Kilby et al., 1998; Wild et al.,
1995). The degree to which a particular HIV-1 Env glycoprotein
complex is able to carry out each step can be detected by
measuring the relative susceptibility of each Env to each of
these inhibitors. Differences in the efficiency or rate of these
reactions may have dramatic effects on viral replication.
In this study we sought to define a potential mechanism by
which an AIDS associated R5 HIV-1 clone, *E11, replicates
better than two pre-AIDS clones, 8G9 and 32D2, which were
derived from the same patient 8 and 2 years earlier respectively.
The contribution of Env to the observed enhanced replication
was examined. We show here that the AIDS clone from patient
ACH142, *E11, is better able to initiate replication than the two
pre-AIDS clones (8G9 and 32D2) from the same patient. Our
results demonstrate that the AIDS associated R5 HIV-1 env
gene mediates a higher degree of infection. This is most likely
explained by the greater usage efficiency of this Env protein for
CCR5 and not broadened coreceptor tropism or differences in
CD4 affinity or gp120 expression. We show further that the R5
AIDS HIV-1 env gene mediates a more rapid rate of infection
than the R5 pre-AIDS HIV-1 env genes. The relevance of these
differences to the in vivo infection is discussed.
Results
R5 AIDS HIV-1 clone, *E11, entered cells more efficiently than
pre-AIDS clones
Previously, we found that R5 HIV-1 clones isolated after
progression to AIDS were better able to replicate and deplete
CD4+ thymocytes in the SCID-hu thy/liv model system than
those isolated before the onset of AIDS (Scoggins et al., 2000).
In order to evaluate which steps in the HIV-1 life cycle differed
between three of these original biological clones, two clones
that were isolated prior to the onset AIDS and one that was
isolated after the diagnosis of AIDS, we measured the amount
of initial reverse transcription product (strong-stop DNA)
produced following a single round of infection. We used a
single cell suspension of freshly isolated thymocytes as target
cells. These cells were infected with several doses of virion-
associated p24 to determine the minimal infectious dose of each
viral clone that would yield detectable strong-stop DNA. We
could detect strong-stop DNA production by the early clones
when 4000 or 1000 pg of virion associated p24 were used, but
these clones did not show detectable production of strong-stop
DNA at lower infectious doses (Fig. 1A). In contrast, strong-
stop DNA production could be detected following infection
with as little as 250 pg of *E11 virion associated p24. We
evaluated the efficiency of each infection up to the reverse
transcription stage by expressing the number of HIV-1 DNA
copies per cell as a function of the amount of virion-associated
p24 used in the infection (Fig. 1B). This analysis demonstrates
that the *E11 AIDS R5 HIV-1 required fewer viral particles to
Fig. 2. Patient ACH142 clones are similarly inhibited in the presence of the
CCR5 antagonist, TAK-779. Fresh fetal thymic tissue was divided into 8 mm3
pieces and maintained in rich media on a floating raft. Three thymic pieces were
infected with 1,500 TCIDs of each virus listed. For each virus, a duplicate
infection was done in the presence of 10 μM TAK-779. TAK-779 was
maintained in the cultures throughout the experiment. Every 2 days, 1/10th of
the media was removed and fresh media was added. Media was frozen and used
for reverse transcriptase (RT) assay. The values for day 7 are shown. RT activity
above background was determined by the following formula: (RTActivity−RT
Activity of the Uninfected Control) / (RT Activity for the Uninfected Control).
For samples treated with TAK-779, the Uninfected Control treated with TAK-
779 was used. The average values from two separate infections are shown ± the
standard error of the mean. *The value is significantly different from the value
for the *E11 sample (p-value<0.05). **The value is significantly different from
the value for the NL4-3+TAK-779 sample (p-value<0.05).
Fig. 1. The R5 AIDS clone *E11, is more efficient in a single round infection of
fresh thymocytes. A single cell suspension of fresh thymocytes was infected
with equivalent virion associated HIV-1 p24 in the presence of 4 μg/ml
polybrene. Twenty-four hours post-infection, DNA was isolated. Each DNA
sample was used in real time PCR assays for HIV-1 strong-stop (SS) DNA and
human β-globin gene. HIV-1 DNA copies per cell was calculated as follows:
number of HIV-1 SS DNA copies/1/2×number of β-globin copies). (A) 4000 pg
(gray bar), 1000 pg (dark gray bars), 500 pg (light gray bar), 250 pg (black bar)
of virion-associated p24 as determined by subtilisin resistance were added to
5×105 thymocytes. The average of three infections is shown. (B) The efficiency
of infection was determined for each infection shown in A. This was calculated
as follows: percent infection efficiency=(HIV-1 DNA copies/cell×5×105
cells)/(pg p24×1 g/1012 pg×1 mole/24000 g×6.022×1023 molecules/mole/
3500 p24 molecules/virion)×100. Asterisks denote samples that were
significantly different from the *E11 sample by Student's t test (p-value<0.01).
25K. Olivieri et al. / Virology 358 (2007) 23–38produce detectable amounts of strong-stop DNA in thymocytes
when compared to the pre-AIDS R5 HIV-1 32D2 and 8G9.
Patient ACH142 biological clones were R5 tropic in fetal
thymic organ culture
Expanded coreceptor tropism is one potential explanation
for the enhanced entry efficiency of the AIDS clone.
Previously, we demonstrated that the biological clones studied
here did not form syncytia in the MT-2 assay, did not replicate
in any but CCR5 bearing GHOST reporter cells, and did not
replicate in PBMC from a CCR5 Δ32 homozygote (Scoggins
et al., 2000). To determine if these patient-derived biological
clones were able to replicate using a potential unknown
coreceptor expressed in the thymus, fetal thymic organ culture
(FTOC) was used. Each biological clone was used to infect
individual 8 mm3 pieces of fetal thymus in the absence or
presence of TAK-779, a CCR5 antagonist. The media was
sampled every other day and saved for reverse transcriptase
(RT) assays. After 12 days in culture, all media samples were
analyzed for RT activity and quantified with a phosphorimager(Molecular Dynamics). None of the three ACH142 clones
replicated in the presence of TAK-779. The average values for
day seven when viral replication was at or near peak values
are shown in Fig. 2. No statistical difference was observed
between the level of replication of the *E11 clone and the 8G9
clone in the absence of TAK-779. There was a slight
difference (23%) between the RT activity of the untreated
32D2 and *E11 clones (p-value=0.044). The lack of striking
difference in RT activity was likely due to induction of CCR5
expression in the thymocytes by IL-2, IL-4 and IL-7. We
previously noted that FTOC with these cytokines masked
differences in the replication and CPE of diverse R5 HIV-1
clones (Choudhary et al., 2005). Each of the treated ACH142
samples was significantly different from the treated NL4-3
sample (p-value=0.05). No statistical difference was observed
between the NL4-3 untreated and treated samples. Thus, non-
specific effects of TAK-779 on HIV-1 replication were not
detected in this assay and are therefore not a likely explanation
for the nearly complete inhibition of ACH142 clone replica-
tion by TAK-779. Overall, these data show that use of
coreceptors other than CCR5 does not contribute to the
replication or CPE of the *E11 R5 AIDS HIV-1 clone or either
of the two pre-AIDS clones in human thymocytes.
Isolation and sequencing of the env genes from ACH142 R5
HIV-1 clones
To understand the contribution of env to the enhanced
replication seen with the R5 AIDS HIV-1 biological clone, we
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ACH142-*E11 and 6 molecular env clones from each of the two
pre-AIDS biological HIV-1 clones from the same patient,
ACH142-32D2 and ACH142-8G9, using PCR amplification of
DNA from infected HeLa-CD4-CCR5 cells. The use of several
clones allowed us to investigate the fidelity of our amplification
procedure and to confirm the clonal nature of the original
patient derived viral stocks. The 5′ primer was homologous to a
region that stretched from the middle of the vpu gene to the start
site of env translation. The 3′ primer was homologous to a
conserved region in the nef genes of these HIV-1 clones that we
had previously isolated and sequenced (KO et al., manuscript in
preparation). The env clones were subjected to sequencing and
the predicted amino acid sequences from clones with complete
open reading frames were used to generate a phylogenetic tree
(Fig. 3) and the consensus sequences were analyzed by Clustal
W alignment (Fig. 4). All the patient ACH142 Env amino acid
sequences showed a common ancestry and clustered away from
sequences derived from other HIV-1 clones (Fig. 3). On
average, an evolutionary distance of 1% separated each
predicted Env amino acid sequence derived from the same
biological clone, consistent with limited culture post-cloning by
limiting dilution. Among Env amino acid sequences derived
from the three patient ACH142 biological clones, the *E11
AIDS Env sequence is most distantly related to the earliest pre-
AIDS sequence, 8G9 (83% identity) while it shared 86%
sequence identity with the 32D2 Env. The sequence divergence
between these molecular clones correlates with the time
between isolation of the biological clones from which they
were derived. The Clustal W alignment (Fig. 4) revealed aFig. 3. Patient ACH142 R5 HIV-1 Env sequences cluster away from several
well-characterized reference strains. This phylogram of complete Env amino
acid sequences from ACH142 clones and selected reference isolates is based on
Clustal W alignments and similarity scores. Patient ACH142 HIV-1 clone env
genes were amplified by PCR, cloned and sequenced. Predicted amino acid
sequences were compared to ADA, JR-CSF, JR-FL, NL4-3, and HXB2 Env
sequences, obtained from GenBank. Individual env clones from each patient
ACH142 HIV-1 biological clone are indicated by a letter (A, B or C).
Evolutionary distance, as shown in the phylogenetic tree, is equal to the number
of amino acid sequence differences divided by the total number of amino acid
residues in the predicted last common ancestor.
Fig. 4. Env from the R5 AIDS clone *E11 shows several significant changes
when compared to the Envs from the pre-AIDS clones, 32D2 and 8G9. A Clustal
W alignment of selected segments of the consensus sequence of each Env is
shown. Gaps in the alignments are represented by dashes. Bold amino acid
residues represent changes of interest between clones. The numbers above each
segment indicate the corresponding amino acid number of the N-terminal
residue of the segment in the HXB2 Env. The consensus sequences shown here
correspond to the following sequences in Fig. 3: 8G9-B, 32D2-B and *E11-C.widely variable gp120 moiety and a highly conserved gp41
moiety. The most interesting changes among the gp120
variations occur in the V1, V2, V3, and C4 regions. In V1
there was a gradual extension and an increase in potential N-
linked glycosylation sites over time, from the earliest clone,
8G9, to the last clone, *E11. In the C terminal portion of the V2
loop, however, there was a reduction in the number of potential
N-linked glycosylation sites for 4/9 *E11 clones studied. In a
region forming part of the bridging sheet (N-terminal segment
of C2), which interacts with CCR5, there was also a change
from a valine at position 200 in the pre-AIDS gp120 to a
threonine in the AIDS gp120. In the V3 loop, there was a
chronological increase in the basic nature of the region. The
AIDS gp120 also contained a proline at position 308 where the
pre-AIDS gp120s had a threonine. In the C4 region there were
two changes: a serine residue was present at position 440 in the
*E11 gp120 where there was a lysine or an arginine in the
Fig. 5. The R5 AIDS *E11 env gene mediates greater infectivity than the two R5
pre-AIDS env genes. The B4.14 HIV-1 packaging cell line was co-transfected
with pTR167-Δnef (5 μg), *E11, 32D2, or 8G9 pCMV-env (5 μg), pCMV-tat
(2 μg), 8G9 pCMV-nef (2.5 μg). Three days post-transfection, 10 or 100 μl of
the cell supernatants, as indicated, were used to infect 2×105 HeLa-CD4-CCR5
cells in the presence of 8 μg/ml DEAE-dextran. Virus and cells were incubated
together at 37 °C for 24 h then media was removed and replaced with IMDM+
10% BCS. At 48 h post-infection, IMDM+10% BCS and hygromycin
(200 μg/ml) was added. After 2 weeks of selection, resistant colonies were
stained with crystal violet and manually counted. The average of six infections
from two different viral stocks is shown for each env gene. Error bars represent
standard errors of the means (SEM). The fold differences between samples are
shown. Asterisks denote samples that were significantly different from the *E11
sample by Student's t test (p<0.01).
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position 442 in the two pre-AIDS gp120 to a leucine residue at
this position in the later AIDS associated clone. In contrast, no
changes were seen in the residues involved in direct contact
with CD4. In gp41, there were several changes in sequence. The
most significant change was the change of an arginine at
position 790 in 8G9 to a tryptophan in clones 32D2 and *E11.
This position is in the region between lentiviral lytic peptides 1
and 2 (LLP-1 and LLP-1). LLP-1 and LLP-2 are cationic,
helical regions of the cytoplasmic tail of gp41 that have been
reported to have membrane perturbing effects (Chen et al.,
2001; Chernomordik et al., 1994; Comardelle et al., 1997;
Miller et al., 1993). Residues involved in the contact regions of
the six-helix bundle (Furuta et al., 1998; Weng andWeiss, 1998)
were absolutely conserved, although some changes in the non-
contact residues of the bundle were observed.
R5-AIDS clone *E11 env mediated infection more efficiently
than R5 pre-AIDS clone 32D2 or 8G9 envs
In order to evaluate the contribution of each HIV-1 env gene
to infectivity, the retroviral packaging cell line B4.14, was used
to produce hygromycin resistance-encoding, replication defec-
tive HIV-1 vectors (Srinivasakumar et al., 1997). GagPol+ Rev+
B4.14 cells were co-transfected with the vector plasmid,
pTR167-Δnef, plus pCMV-tat, pCMV-8G9-nef and with a
pCMV-env expression vector for the most common *E11, 32D2
and 8G9 env genes, the partial predicted amino acid sequences
of which are shown in Fig. 4. Complete nucleotide sequences
are available from GenBank under the following accession
numbers: DQ178989, DQ178990, and DQ178991 respectively.
Three days post-transfection, the supernatants were collected
and 100 μl or 10 μl of this supernatant were used to infect HeLa-
CD4-CCR5 cells. After 2 weeks of hygromycin selection, the
resultant colonies were stained with crystal violet and manually
counted (Fig. 5). The *E11 env gene mediated a statistically
significant higher degree of infection than either of the two
earlier env genes at both the high dose (100 μl) and the low dose
(10 μl). At the 100 μl dose, the infection mediated by the *E11
env gene was 2.1-fold and 4.7-fold higher than then infection
mediated by 8G9 and 32D2, respectively. When 10 μl of
infectious supernatant were used, the infection mediated by the
*E11 env gene was 22.2 and 49.4 times higher than infection
mediated by 8G9 env and 32D2 env, respectively.
We analyzed the expression level of each env gene to
determine if this was a factor in mediating the increased
infectivity of virions pseudotyped with the *E11 Env.
Quantitative western blots, using infrared detection, on lysates
of transfected B4.14 cells and virions produced as described
above for Fig. 5, were performed (Fig. 6). This allowed accurate
quantification of specific bands, yielding a determination of the
amount of gp120 in each cell lysate and virion preparation. We
found that gp120 expression was equivalent for the pre-AIDS
envelopes and the AIDS env, both in transfected cells and on
virions. The transfected B4.14 cells showed prominent gp160
and gp120 bands, while the virions had stronger gp120 bands
but retained some gp160.R5 AIDS *E11 Env protein showed similar CD4 interaction
efficiency but higher CCR5 interaction efficiency than
pre-AIDS Envs
To further elucidate the mechanism by which the *E11 Env
mediated a higher level of infection, we measured the difference
in relative susceptibility to two entry inhibitors, the CD4 MAb
B4 and the CCR5 antagonist TAK-779 (Fig. 7). Using B4.14
cells to generate a hygromycin resistance vector stock
pseudotyped with each patient env gene studied here, we
performed infections in the presence of each inhibitor at a range
of concentrations. Virus and inhibitor were incubated with
HeLa-CD4-CCR5 cells for 24 h at 37 °C. After 2 weeks of
hygromycin selection, resistant colonies were stained with
crystal violet and manually counted. In order to make
comparisons of the relative resistance to each inhibitor for
virions pseudotyped with each patient Env, the number of
colonies generated at each dose of inhibitor was normalized to
the number of colonies when no inhibitor was added. This
generated the fraction of total infectivity for each dose. When
the dose of inhibitor was plotted versus the fractional infectivity,
the IC50 for each inhibitor was calculated using Prism software
(GraphPad). The calculated IC50 values of the CD4 MAb B4
(Fig. 7A and Table 1) indicate that the *E11 Env had
approximately a 1.5-fold to 2-fold greater resistance to
inhibition by MAb B4 than the two earlier Envelope proteins.
The difference between the resistance mediated by *E11 env
and 8G9 env was not statistically significant. More strikingly,
Fig. 6. The R5 AIDS env gene and the two R5 pre-AIDS env genes produced equivalent amounts of gp120 on transfected cells and virions. (Upper panels) Western
blot showing gp120 and gp160 produced in B4.14 cells transfected with pTR167ΔNef (5 μg), *E11, 32D2, or 8G9 derived pCMV-env (5 μg), pCMV-Tat (2 μg) and
pCMV-*E11-nef (2.5 μg) and on virions produced by the transfected cells. Membranes were probed with rabbit anti HIV-1 Env 343 serum (1:250 dilution) overnight at
4 °C, washed and probed with goat anti-rabbit IgG–Alexa Fluor 680 (1:50,000 dilution), then analyzed with the LI-COR Odyssey infrared imaging system. (Lower
panels) Virion and cell lysate gp120 levels were quantified with the LI-COR Odyssey infrared imaging system.
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than the other envelope proteins. It was almost 7-fold more
resistant to TAK-779 than 32D2 and more than 143-fold more
resistant than 8G9 Env (Fig. 7B and Table 1). Similarly, the
*E11 biological clone was more resistant to inhibition by the
CCR5 MAb 2D7 than the pre-AIDS clones (data not shown).
These results indicate that the *E11 Env has greater usageFig. 7. *E11 pseudotyped vectors are more resistant to entry inhibitors than vectors p
from the packaging cell line B4.14 co-transfected with pTR167-nef (5 μg), *E11 (O),
*E11-nef (2.5 μg). Three days post-transfection, 100 μl (A) or 33 μl (B) of these supe
listed in a total volume of 1 ml. The CD4 monoclonal antibody B4 was used in A and
incubated with cells for 24 h before the media was aspirated and replaced. Colony sele
values of six infections from two different viral stocks ± the SEM are shown.efficiency for CCR5 than the related pre-AIDS envelope
proteins derived from clones 32D2 and 8G9. Non-specific
effects of TAK-779 were evaluated in the same assay system.
The X4 tropic NL4-3 env was used to pseudotype hygromycin
resistant virions. These virions were used to infect HeLa-CD4-
CCR5 cells in the presence or absence of TAK-779. No effect of
TAK-779 was seen on infectivity of NL4-3 (data not shown).seudotyped with either 8G9 or 32D2 envs. Infectious supernatants were obtained
32D2 (▪), or 8G9 (▴) derived pCMV-env (5 μg), pCMV-tat (2 μg) and pCMV-
rnatants were added to HeLa-CD4-CCR5 cells simultaneously with the inhibitor
TAK-779 was used in panel B. In both panels A and B, inhibitor and virus were
ction and enumeration were done as described in materials and methods. Average
Fig. 8. *E11 env gene mediates more rapid infection than 32D2 or 8G9 env
genes. One hundred μl of *E11 env (O), 32D2 env (▪) or 8G9 env (▴)
pseudotyped HIV-1 vector was used to infect 2×105 HeLa-CD4-CCR5 cells.
For replicate infections, the infectious supernatant was removed and replaced
with normal media containing 1.8 μg/ml of T-20 at 15 min, 30 min, 1, 3, 6 and
12 h post-infection. Inhibitor containing media was removed 24 h post-infection
and replaced with normal media. Selection with hygromycin was begun 48 h
post-infection and continued for 10 days with media changes every 2 days. At
the end of selection the colonies were counted manually. The fractional
infectivity was calculated as the number of colonies resulting from each time
point when T-20 was added, divided by the number of colonies resulting from
the 24 h incubation of virus with target cells. A non-linear regression analysis of
results from triplicate infections done with each of two viral stocks for each
patient env gene is shown ± the SEM.
Table 1
Comparison of Env mediated entry phenotypes from Patient ACH142 Envs
Env gene Fold difference a
*E11 32D2 8G9 *E11:32D2 *E11:8G9
B4 IC-50 (nM) 2.08±0.18 0.93±0.20 1.44±2.72 2.23 b 1.44
TAK-779 IC-50 (μM) 0.98±0.378 0.14±0.036 0.007±0.0006 7.01 b 143.54 b
50% Infection (h) 3.41±0.09 5.15±0.18 6.32±0.60 0.66 b 0.54 b
a Fold difference was determined by dividing the value for the *E11 property by the value for the 32D2 or 8G9 property.
b Difference was statistically significant by Student's t test (p-value<0.01).
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inhibited by B4 MAb, we observed an increase in infectivity for
all Env pseudotypes at low doses of B4. This may be due to the
increase in cell surface CD4 expression seen when low doses of
B4 were administered to HeLa-CD4-CCR5 cells (data not
shown). This upregulation of CD4 expression was also seen
following incubation with another CD4 MAb, Sim.4, which
resulted in a similar increase in HIV-1 infectivity when low
doses were administered (data not shown).
The R5-AIDS env conferred more rapid cell entry than
pre-AIDS envs
We next measured the entry rate by performing infections
with Env pseudotyped hygromycin resistance vectors, similar to
the ones described above. In this case, we added a nearly
completely inhibitory dose of the entry inhibitor T-20 at
different times post-infection. This concentration was deter-
mined by titration of T-20 in a parallel assay (data not shown).
The number of colonies resulting from addition of T-20 at each
time point, with each Env was normalized to the number of
colonies achieved when T-20 was added 24 h post-infection to
vector pseudotyped with each Env; when plotted versus time,
this produced a fractional infection curve for infection mediated
by each Env (Fig. 8). We analyzed this curve with Prism
software (GraphPad) to determine the time at which 50% of
viral entry was completed. We calculated that the time to 50%
entry for the *E11 Env pseudotyped vector occurred in 2/3 of
the time it took for the 32D2 Env pseudotyped vector. The *E11
Env pseudotyped vector achieved 50% entry in 1/2 the time it
took for the 8G9 Env pseudotyped vector (Table 1). Thus, the
*E11 Env pseudotyped vector showed an increased rate of entry
when compared to 32D2 Env pseudotyped vector and an even
greater increase when compared to 8G9 Env pseudotyped
vector.
R5 AIDS env recombinant HIV-1 achieved higher viral load
and caused greater CPE in SCID-hu thy/liv grafts than a
pre-AIDS env recombinant virus
To investigate whether the phenotypic differences we
observed between the AIDS and pre-AIDS envs in vitro
contributed to the enhanced replication and cytopathic effects
of the *E11 AIDS HIV-1 clone in SCID-hu mice, we altered a
JR-CSF provirus so that it contained the V1–V5 Env encoding
segment of each of the patient isolates. This region was
amplified from DNA isolated from infected PBMC, usingprimers to well-conserved regions of the HIV-1 env gene. The
amplified DNA was cut with DraIII and MfeI and then cloned
into πSV-JR-CSF cut with the same enzymes, thereby
replacing the V1–V5 encoding region of the JR-CSF env
gene with the V1–V5 encoding region of the patient ACH142
R5 HIV-1 clones 32D2 and *E11. Viral stocks were made by
transfection of 293T cells and titered on activated PBMC.
Equivalent multiplicities of infection were then used to infect
human fetal thymus/liver grafts in SCID mice (SCID-hu thy/liv
grafts), the construction and use of which have been previously
described (Camerini et al., 2000). At 8 weeks post-infection,
the grafts were harvested and each graft was made into a single
cell suspension. A portion of this suspension was analyzed for
CD4 and CD8 cell surface expression by flow cytometry. The
late stage V1–V5 recombinant HIV-1 clone was better able to
reduce the number of total CD4+ thymocytes than the pre-
AIDS 32D2 env recombinant or the parental HIV-1 molecular
clone, JR-CSF in a statistically significant manner (Fig. 9A).
From another portion of the same single cell suspension, a total
intracellular DNA preparation was made. These samples were
subjected to real time PCR to detect, in separate reactions,
Fig. 9. JR-CSF (*E11 V1–V5) achieved higher replication and induced greater CD4+ thymocyte loss in SCID-hu thymus/liver graft infections than JR-CSF (32D2
V1–V5) or JR-CSF. At 8 weeks post-infection, a piece of each infected SCID-hu thy/liv graft was removed and a single cell suspension was made. This was analyzed
for cell surface expression of CD4 by flow cytometry and for the presence of HIV-1 strong-stop DNA. (A) Summary of percent CD4+ cells in all infected grafts at 8
weeks post-infection. (B) HIV-1 strong-stop DNA detected per 105 cells in each infected graft at 8 weeks post-infection. Cells from the same single cell suspension
used in A were used to make a total intracellular DNA preparation which was measured by a real time PCR assay to detect HIV-1 strong-stop DNA and β-globin
copies. The number of HIV-1 DNA copies was normalized to cell number by measuring the number of β-globin genes in the DNA sample. These values are shown
minus the background level of detection as determined in uninfected samples. Asterisks indicate values that were significantly different by Student's t test from the
*E11 sample (p-values are as indicated). The N values below each bar are equal to the number of samples in each set.
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numbers for HIV-1 strong-stop DNA were normalized to β-
globin copy numbers to obtain the number of HIV-1 genomes
per 105 cells in each sample. The late stage recombinant virus
accumulated approximately 10-fold more viral DNA than the
pre-AIDS recombinant and approximately 6-fold more than the
parental HIV-1 clone JR-CSF indicating that the *E11 V1 to
V5 env region increased viral replication (Fig. 9B). Never-
theless, this difference in viral replication did not reach
statistical significance due to the small sample size. The p-
values for the Student's t test comparing the samples infected
with the *E11 recombinant to the samples infected with the
pre-AIDS recombinant or the parental HIV-1 clone JR-CSF
were 0.38 and 0.42, respectively. The FACS and real-time PCR
data combined show that the late stage V1–V5 region of
gp120 mediated increased replication and cytopathic effects.Discussion
The env gene from the HIV-1 AIDS R5 isolate *E11 is an
important determinant of the enhanced replication of this clone
compared to env genes from the two HIV-1 clones isolated from
the same patient earlier in infection, prior to the onset of AIDS.
We used the original biological clones to investigate whether
these viruses differed in their ability to enter cells and initiate
reverse transcription. The *E11 original biological clone was
able to initiate reverse transcription at doses of virus where the
two pre-AIDS clones were unable to do so. We also observed
that the efficiency with which the *E11 virus was able to do this
increased as the infectious dose was lowered. Because the
viruses differed measurably in the initiation of reverse
transcription, we hypothesized that viral entry or other steps
prior to reverse transcription initiation were responsible for the
differences seen between the viruses. Other factors besidesentry enhancement may have played a role in determining the
enhanced replication seen in the SCID-hu model, but we chose
to focus on Env-mediated entry because it may be a rate-
limiting step in the viral life cycle.
Some potential causes for the difference in entry efficiency
between the R5 AIDS HIV-1 biological clone and the R5 pre-
AIDS HIV-1 biological clones are broadened coreceptor
tropism, enhanced Env expression, enhanced usage efficiency
for CD4, and enhanced usage efficiency for coreceptor. We
investigated each of these individually. Broadened coreceptor
tropism was not found to be a factor in the difference in
replication between the AIDS biological clone *E11 and the two
pre-AIDS biological clones, 8G9 and 32D2. Previously we
found that no ACH142 clone, or env recombinant virus made
from these clones, was able to replicate in GHOST reporter cell
lines expressing CCR1, CCR2b, CCR3, CCR4, CCR8,
CXCR4, Bonzo, BOB or V28, but all replicated in GHOST-
CCR5 cells (Scoggins et al., 2000). Moreover, we also
demonstrated that these isolates did not replicate in activated
PBMC from a CCR5 Δ32/Δ32 individual and that the
replication of *E11 was greatly reduced in a CCR5 Δ32/wt
CCR5 SCID-hu thy/liv graft. The addition of TAK-779 to an
FTOC infection in this study allowed us to elucidate the tropism
of each isolate in a model system similar to one where the
isolates were seen to differ the most. None of the clones was
able to replicate in the presence of TAK-779, confirming the
apparent absolute R5 tropism of each HIV-1 clone. Further-
more, we have demonstrated that the ACH142 Env pseudo-
typed vectors studied here are not able to infect HeLa-CD4
cells, unless they are engineered to express CCR5 (data not
shown). Expanded tropism is therefore an unlikely explanation
for the enhanced replication of the AIDS isolate seen here.
We evaluated the impact of the three env genes on viral
infectivity using an HIV-1 hygromycin reporter vector
pseudotyped with each of the patient Envs. In this assay, we
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infectivity than either of the two pre-AIDS env genes. We
evaluated the possibility that this effect might be due to
increased expression of the AIDS associated gp120 and found
no significant differences in gp120 expression on transfected
cells or virions. Since expression level variation did not
explain the difference in the phenotype of the env genes, other
mechanisms that allowed the *E11 Env to mediate a higher
level of infection must exist. Titration of a CD4 blocking
antibody showed a 1.4- to 2.2-fold lower sensitivity of the
*E11 env gene with respect to the 8G9 and 32D2 env genes.
When similar experiments were done with the CCR5
antagonist, TAK-779, the *E11 env gene was approximately
7-fold more resistant to inhibition than the 32D2 pre-AIDS env
gene and approximately 143-fold more resistant to inhibition
by TAK-779 than the 8G9 pre-AIDS env gene. Similar results
were obtained with the anti-CCR5 MAb, 2D7. This large
difference may result from a difference in the efficiency with
which each Env interacts with CCR5. Moreover, we confirmed
that the *E11 env gene did not mediate infection of cells that
were not expressing CCR5. Based on this we conclude that the
*E11 env gene more efficiently mediates productive fusion due
to an increase in CCR5 usage efficiency.
The chronological increase in TAK-779 resistance in patient
ACH142 derived HIV-1 clones is striking. This difference helps
explain the increase in infectivity seen in the model system used
here and the larger difference that was seen when the original
biological clones from patient ACH142 were used to infect
SCID-hu thy/liv grafts (Scoggins et al., 2000). An Env protein
with higher CCR5 usage efficiency, like that of the *E11 AIDS
Env, allows more virions to productively enter target cells. This
property might be particularly important when target cells
express limiting amounts of CCR5, as do thymocytes.
Increases in coreceptor interaction efficiency were predicted
to also have effects measurable in a single round of replication.
Using a kinetic analysis of infectivity by the HIV-1 hygromycin
reporter vector, we showed that the *E11 Env pseudotyped
vector achieved 50% entry and reached maximum entry more
rapidly than vectors pseudotyped with either of the two pre-
AIDS Env proteins. When the infection rate was measured
strictly as the number of resultant colonies, not the fractional
infectivity, *E11 mediated a 4-fold higher rate of infection as
measured by colonies per hour. This indicates that the *E11 Env
protein mediated more rapid infection due to faster entry. This
may play an important role in natural infections by allowing the
virus to avoid antibody-mediated destruction and to increase its
total replicative potential.
The 8G9 Env pseudotyped vector did not reach a plateau
level of infection until 24 h post-initiation of infection. This
slow fusing phenotype might impart an advantage in the
establishment of infection. An early stage, pre-AIDS virus,
similar to 8G9, may adsorb onto a dendritic cell when it first
enters the previously uninfected individual. If the virus were to
quickly infect a dendritic cell, it might be “locked” inside the
DC. It could only spread to other cells when the dendritic cell
allowed viral production. Because DC are reported to support
much lower levels of viral production than activated T cells, itwould be advantageous for the virus to replicate in T cells. A
slower fusing virus would be more likely to be carried by the
DC to an area of high T cell density, like a lymph node.
Dissociation of HIV-1 by reversal of the gp120/CD4/CCR5
interaction or the gp120/DC-SIGN interaction would allow the
previously associated virus to be transferred to a T cell, which
would allow greater viral replication.
Using Env V1–V5 JR-CSF recombinant virus, we showed
that this region of Env can modulate the replication and CPE
mediated by HIV-1 in a SCID-hu thymus/liver model. In this
system, the recombinant JR-CSF bearing the V1–V5 from the
AIDS *E11 Env depleted more CD4 thymocytes and
replicated to a higher level on average. Based on all our
data we conclude that the enhanced CCR5 usage efficiency of
the *E11 AIDS Env is the most likely explanation for this
observed increase in CD4+ thymocyte depletion and viral
replication.
Several possible causes of the phenotypic differences
between the Env proteins studied here are indicated by their
predicted amino acid sequences. In the C2 region, in a stretch
of residues responsible for forming the bridging sheet which
comes into contact with the coreceptor (Kwong et al., 1998),
there was a threonine in the AIDS clone where there was a
valine in the pre-AIDS clones. This may alter the ability of the
AIDS clone to interact with CCR5 since a valine to serine
mutation at this position had a modest negative effect on
CCR5 affinity of another R5 HIV-1 gp120 (Rizzuto et al.,
1998). Changes also exist in the V3 loop, where the R5-AIDS
Env showed an increase in the positive charge of the loop,
which may allow more efficient interaction with sulfated
tyrosines in the amino-terminal domain of CCR5. There is
also a proline in the AIDS clone and a threonine in the pre-
AIDS clones at position 308 of the V3 loop. Furthermore, the
C4 region of the *E11 env has a glutamine to leucine change
compared with the earlier Env's that has been reported to
confer a 2-fold increase in CCR5 affinity in another R5 HIV-1
gp120 (Rizzuto et al., 1998). *E11 Env also has a rare amino
acid sequence in the C4 region that differed from the pre-
AIDS clones. Only 7 out of 723 Env sequences reported in the
Los Alamos National Labs HIV-1 database contained both a
serine-440 and a leucine-442. Mutational analysis of all of
these residues may point out the direct molecular mechanism
of the enhanced resistance to TAK-779 shown by the AIDS
Env and the differences in replication and CPE it confers
compared to the pre-AIDS Envs.
The proline 308 residue was first identified when escape
mutants were selected in vitro in the presence of the CCR5
antagonist, AD101 (Kuhmann et al., 2004). This raises the
possibility that clinical use of CCR5 antagonists could give
rise to isolates with CCR5 usage similar to the AIDS clone
studied here. These drug-resistant isolates may also show
increased ability to replicate and cause cytopathic effects in
the thymus. In comparison, escape mutants from RT or
protease inhibitors often show lower replicative potential
(Croteau et al., 1997; Goudsmit et al., 1996; Maeda et al.,
1998; Martinez-Picado et al., 1999; Sharma and Crumpacker,
1997). Thus, CCR5 antagonists may present lowered benefit
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cause increased cytopathicity. This highlights the clinical
importance of determining the amino acid residues that
contribute to the enhanced replicative potential of AIDS
associated R5 HIV-1 isolates. Although other differences may
exist between the biological clones studied here, the
differences found between the Env proteins clearly play an
important role in the enhanced replication and CPE of the R5-
AIDS HIV-1 clone. This study highlights the importance of
understanding the contribution of Env to the onset of AIDS.
Materials and methods
Cells
Peripheral blood mononuclear cells (PBMC) were obtained
from healthy individuals via fycoll/hypaque gradient centrifuga-
tion as described previously (Scoggins et al., 2000). These cells
were maintained in 10% fetal calf serum (FCS)+gentamicin
(50 μg/ml) in IMDM (Invitrogen). Phytohemagglutinin (PHA)
was added to activate the cells for 2 days. Following PHA
activation, the cells were washed twice in PBS andmaintained in
10% FCS IMDM+gentamicin (50 μg/ml) and 10 units/ml of
IL-2. 293T cells were maintained in 10% bovine calf serum
(BCS) with 1.5 mg/ml of G418 in IMDM. Thymus and liver
tissues were obtained from Advanced Bioscience Resources.
B4.14 cells (Chazal et al., 2001) were maintained in 10% BCS
IMDM+gentamicin (50 μg/ml) and hygromycin (200 μg/ml).
HeLa-CD4-CCR5 cells (Chazal et al., 2001) were maintained
in IMDM+10% BCS, gentamicin (50 μg/ml), hygromycin
(200 μg/ml) and puromycin (3 μg/ml).
Antibodies and inhibitors
The CD4 and control antibodies conjugated to phycoery-
thrin (PE) were obtained from Caltag. The CD8 and control
antibodies conjugated to peridinin chlorophyll protein (PerCP)
were obtained from Becton-Dickinson. The monoclonal
antibody B4 was obtained from the NIH AIDS Reagent
Program and was provided to the program by United
Biomedical Inc. (Wang et al., 1999). TAK-779 was provided
by the Takeda Chemical Corporation (Baba et al., 1999). T-20
was obtained from Trimeris Inc. (Research Triangle, NC).
Rabbit polyclonal anti-343 Env was generated against the
NL4-3 peptide consisting of amino acids 343 to 512 and used
for western blot analysis as described below (Hammarskjöld
et al., 1994).
HIV-1 biological and molecular clones
The HIV-1 biological clones studies here, 8G9, 32D2 and
*E11, were described previously (Scoggins et al., 2000). These
biological clones were isolated in the laboratory of Dr. Hanneke
Schuitemaker from patient ACH142 by limiting dilution on 8/
18/86, 8/25/92 and 4/28/94 respectively and were kindly
provided to us by Dr. Schuitemaker. At the time of isolation,
patient ACH142 had CD4 T cell counts per microliter of 720,310 and 300, respectively (Scoggins et al., 2000). The πSV-JR-
CSF proviral plasmid was described previously (Camerini et al.,
2000). pCMV JR-CSF-env-ΔBglII is based on pCMV-JR-CSF-
env (Chazal et al., 2001). To create the recombinant JR-CSF
provirus containing the V1–V5 env sequence from the
biological clones, pCMV-JR-CSF-env vector was first cleaved
with BglII. The vector portion was isolated by gel extraction
using the Quiagen Quiex II kit as per manufacturer's
instructions and self-ligated to create pCMV-JR-CSF-env-
ΔBglII. The DraIII/XhoI fragment was removed from this
vector and ligated into a DraIII/XhoI digested πSV-JR-CSF.
This yielded πSV-JR-CSF-ΔBglII. To amplify the V1–V5
regions of HIV-1 env, total intracellular DNA was harvested
from PBMC infected by each biological clone studied here.
These regions were amplified with the forward primer
TTATGGGATCAAAGCTTAAAGCCA and the reverse primer
CCCATAGTGCTTCCTGCTGCTCC. The PCR program was
as follows: 2′ at 95 °C, 1′ at 59 °C, 5 min at 72 °C, followed by
40 cycles of 30 s at 95 °C, 30 s at 59 °C, and 1 min at 72 °C.
These were followed by a single cycle of 30 s at 95 °C, 30 s at
59 °C and 5 min at 72 °C. Epicentre Enzyme Mix and Epicentre
Buffer C were used in this reaction. The 1.2 kb fragment was
isolated by gel extraction. This fragment was cloned into
pGEM-T (Promega). Ligations were transformed into DH5α
and screened for β-galactosidase activity. Plasmids contained in
β-galactosidase null colonies were sequenced by the University
of Virginia Biomolecular Core Facility. Clones containing a
deduced amino acid sequence without stop codons in the V1–
V5 region were digested with DraIII and MfeI. This 1.2 kb
fragment was ligated into pCMV-JR-CSF-env-ΔBglII. These
vectors were digested with DraIII and XhoI and the Env
fragment was inserted into πSV-JR-CSF-ΔBglII cut with the
same enzymes. To produce infectious virus, one million 293T
cells were plated in a 10 cm tissue culture plate in non-selective
media. Ten μg of each proviral clone was transfected by the
calcium phosphate method. Two, three and 4 days post-
transfection, the media was collected and replaced. Five
hundred μl aliquots were frozen at −80 °C and used for
titering. Viral titers were determined on two day PHA-activated
PBMC in the presence of IL-2.
Plasmid construction
To construct full-length envelope expression vectors, Patient
ACH142 derived R5 HIV-1 biological clones were used to
infect HeLa-CD4-CCR5 cells (Chazal et al., 2001). Twenty-
four hours post-infection a Hirt extract was made to isolate low
molecular weight DNA. Ten μl of this was used as a template in
a PCR reaction with the forward primer GCAGAAGA-
CAGTGGCAATGAG and the reverse primer GGTACCA-
GAGGTCTGACTGG. The reaction was carried out in 50 μl.
Epicentre Buffer F. Invitrogen Taq (7.5 units) New England
Biolabs Deep Vent (3 units) were used in combination for this
reaction. The PCR program was as follows: 95 °C for 2 min, 40
cycles of 95 °C for 30 s, 62 °C for 30 s, 72 °C for 3:30. This was
followed by 10 min at 72 °C. The 3.2 kb fragment was gel
isolated by Quiex II gel extraction and topoisomerase enhanced
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Biomolecular Core Facility sequenced resulting vectors.
Vectors containing a complete open reading frame for Env
were cut with KpnI and XhoI and the env fragment was inserted
into pCMV-JR-CSF, which was cut with the same enzymes.
pCMV-EGFP was obtained from Clontech and pNL4-3 from
Dr. Malcolm Martin of the NIH. pTR167 Δnef was described
previously (Chazal et al., 2001; Srinivasakumar et al., 1997).
Sequence analysis
Sequencing was done by the University of Virginia
Biomolecular Core Facility using Applied Biosystmem's
BigDye Terminator labeling chemistry with AmpliTaq poly-
merase FS. The universal M13 forward and reverse primers
were used to initiate a primer walking strategy. Following the
initial sequencing, a primer complimentary to the known
sequence was generated and used to sequence further into the
clone. This process was repeated until the entire gene was
sequenced. When ambiguous sequence was generated, a
different internal primer was used until unambiguous results
were achieved. Clustal W sequence alignments and phyloge-
netic trees (Higgins et al., 1996) were generated on the
European Bioinformatics Institute web server located at http://
www.ebi.ac.uk/clustalw. Evolutionary distance, as shown in
the phylogenetic tree, is equal to the number of amino acid
changes divided by the total number of amino acid residues in
the predicted last common ancestor (Ogurtsov et al., 2004).
Complete nucleotide and predicted amino acid sequences
are available on the GenBank server under the following
accession numbers: DQ178989 (*E11), DQ178990 (32D2),
and DQ178991 (8G9).
SCID-hu thy/liv grafts
SCID-hu thy/liv grafts were prepared as previously
described (Scoggins et al., 2000). On the day of infection, the
graft was exposed and injected with 5000 TCID50 of HIV-1 in
50 μl via a tuberculin syringe. The incision into the mouse was
sutured. Following 8 weeks of infection, a portion of the graft
was removed. A single cell suspension was made by mincing
the tissue in 5 ml of IMDM on ice. The suspension was poured
through a 70 μm nylon mesh filter. The filter was then washed
with 5 ml IMDM. The cells were then pelleted in a tissue culture
centrifuge and resuspended in PBS. The cells were partitioned
to be studied by FACS analysis or to be used for DNA
extraction. One million cells that were to be used for FACS
analysis were pelleted and resuspended in 200 μl PBS+0.02%
NaN3 (PBSA) and pelleted again. Cells were resuspended in
200 μl PBSA+2% fetal bovine serum (FBS). Two μl of CD4-
PE antibody (Caltag) and 10 μl of CD8-PerCP antibody
(Becton-Dickinson) were added to each sample. Cells from a
mock infected graft were used as single antibody controls, no
antibody control and isotype (IgG2a-PE, IgG1-PerCP) controls.
Samples were run on a Becton Dickinson FACSCalibur and
analyzed with CellQuest software to determine percent positive
for CD4, CD8 or both.Western blot analysis
Western blots of cell lysates and virions were performed
essentially as described previously (Alexander et al., 2004)
except that quantitation was performed by infrared imaging with
a LI-COR Odyssey infrared imager. Briefly, 60 h after
transfection B4.14 cells were lysed in 200 μl of lysis buffer
(50 mM Tris HCl, pH 7.4, 150 mMNaCl, 1 mM EDTA, and 1%
Triton). Cell lysates were then subjected to Bradford dye-
binding assay (Bio-Rad, Hercules, CA). Virus was harvested and
centrifuged at 1,500 RPM for 5 min to remove cellular debris.
The supernatant was then subjected to ultracentrifugation at
30,000 RPM in an SW41Ti rotor (Beckman) for 1 h. Pelleted
virions were resuspended in 100 μl of phosphate-buffered saline
at 4 °C overnight, and the levels of p24 in concentrated virion
stocks were determined by enzyme-linked immunosorbent assay
(ELISA). Equal amounts of virion p24 and cell lysate protein
were added to SDS loading buffer and then boiled for 5 min, and
the supernatant was loaded onto a 12% polyacrylamide gel.
Proteins were separated by SDS-PAGE and then transferred to
Immobilon membranes (Millipore, Bedford, Mass.). Mem-
branes were probed with rabbit anti HIV-1 Env 343 serum
(1:250 dilution) overnight at 4 °C, washed and probed with goat
anti-rabbit IgG-Alexa Fluor 680 (1:50,000 dilution), then
analyzed and quantitated with the LI-COR Odyssey infrared
imaging system.
Real time PCR analysis
Total intracellular DNA was prepared using the Quiagen
Quiamp Blood and Tissue kit as per the manufacturer's
instructions. Five μl of DNA was added to SYBRGreen PCR
Master Mix (ABI). Separate reactions were run using primers to
detect HIV-1 strong-stop (SS) DNA or to detect the human β-
globin gene. HIV-1 SS DNAwas detected with 800 nM each of
the 5′ primer AA55 and 3′ primer M667 (Zack et al., 1990). The
human β-globin gene was detected with 800 nM each of the 5′
primer LAI and 3′ primer LAII (Zack et al., 1990). Standards for
real time PCR were made by adding known amounts of HIV-1
provirus to total intracellular DNA from 5×105 uninfected
human PBMC. Dilutions of total intracellular DNA from
PBMCs were used to create a standard curve for quantification
of the human β-globin gene. All reactions were run on an ABI
Prism 7700 real time PCR machine. The threshold level of
amplification was defined as the level of fluorescence that the
standard reactions achieved in the most linear fashion, showing
the highest r2 value. The cycle at which each experimental
reaction reached this threshold level was used to calculate the
number of copies in each sample. SS-DNA/105 cells was
calculated as follows: number of SS-DNA copies/(number of β-
globin copies/2 β-globin copies per cell)×105.
Fetal thymic organ culture (FTOC)
FTOC were carried out as described previously (Choudhary
et al., 2005). Briefly, 8 mm3 pieces of fetal thymus containing at
least three intact thymic lobules were infected with equal
34 K. Olivieri et al. / Virology 358 (2007) 23–38TCID50 or equal p24 amounts of HIV-1 as described in figure
legends. Following overnight incubation with viral stock, the
pieces were removed and placed on a floating raft in Iscove's
medium with 10% fetal bovine serum, minimal essential
vitamins, 50 μg/ml gentamicin (all from Life Technologies,
Rockville, MD) and insulin/transferrin/sodium-selenite media
supplement (Sigma, St. Louis, MO) plus IL-2 (20 IU/ml), IL-4
(0.5 ng/ml) and IL-7 (1 ng/ml). Ten percent of the media was
removed and replaced every other day and saved for reverse
transcriptase analysis. Following 10–12 days of infection, the
thymic pieces were used to create a single cell suspension and
analyzed by flow cytometry for CD4 and CD8 expression using
CD4-PE and CD8-PerCP antibodies. Flow cytometry was run
on a FACSCalibur instrument and analyzed with CellQuest
software (both from Becton-Dickinson).
Reverse transcriptase assay
Ten μl of media collected from FTOC were added to a solution
containing, 5 mMMgCl, 60 mM Tris–HCl, 1 mM EDTA, 0.01%
Triton X-100, 75 mM KCl, 4 mM DTT, 12 μM 32P-dTTP at
3 mCI/μM and 5 μg/ml poly-(rA) • (dT) (Amersham). The
sample was incubated at 37 °C for 2 h. Five μl of the reaction mix
were spotted on Whatman DE81 paper and allowed to air dry.
The paper was washed twice quickly with 200 ml 2× SSC. This
was followed by four 5-min washes in 400 ml 2× SSC. Finally,
the blot was washed twice with 50 ml 95% ethanol and allowed to
air dry. The dry blot was exposed overnight to a phosphorimager
cassette. The cassette was read on a Molecular Dynamics
phosphorimager. Each reaction on the blot was quantified with
ImageQuant software. The values shown are volumes over the
local average background.
Determination of virion associated p24
Virion associated p24 amount was first calculated using a
fractionation technique. One ml of Sephacryl S-1000 was
loaded into a Bio-Rad Poly-Prep chromatography column
(0.8×4 cm), packed by gravity flow, and was rinsed with 5
column volumes of PBS. Two hundred μl of viral supernatant
with or without 0.1% Triton X-100 was loaded directly onto the
column matrix. Five ml of PBS was added and allowed to flow
through the column. Half milliliter fractions were collected.
Each fraction was stored at −20 °C and later used in a p24
ELISA and an RT assay. The Triton treated sample was used to
indicate in which fraction the free, dissociated p24 eluted. For
the untreated samples, virion associated p24 values were
calculated as the amount that eluted before the dissociated
p24. Virion associated p24 was also calculated by quantifying
protease resistant p24. Ten milliunits of Quiagen subtilisin
protease were added to 1 ml of viral supernatant and incubated
at 37 °C for 1 h, then PMSF was added. As a control, samples
were run through the same conditions without the addition of
protease. To verify that the reaction conditions allowed the
degradation of all available p24, a 0.1% Triton X-100 sample
was also analyzed in parallel. The Triton treated samples were
spun over a Microcon filter device to remove the detergent andwere resuspended in media. All samples were then used in a p24
ELISA to quantify p24 presence. The amount of p24 that was
resistant to protease degradation after 1 h was defined as the
virion associated p24 amount. The p24 ELISA was done as
described previously (Wehrly and Chesebro, 1997).
HIV-1 infection of thymocytes
Thymocytes (5×105) prepared from fresh fetal tissue were
resuspended in FTOC media and cultured in 12-well plates
(Choudhary et al., 2005). Defined amounts of virion-associated
p24 of each virus were added to each well as described in the
figure legends. The virus was incubated at 37 °C with the cells
for 12 h. The cells were washed twice with PBS and incubated
for 12 more hours at 37 °C. At 24 h post-infection, DNA was
extracted. The number of HIV-1 SS DNA copies per 105 cells
was determined by real time PCR as described above.
Use of packaging cell lines to make hygromycin resistance
HIV-1 vectors
The B41.4 cell line was described previously (Chazal et al.,
2001; Srinivasakumar et al., 1997). B41.4 cells express HIV-1
gag, pol and rev. One million cells were plated 24 h prior to
transfection in non-selective media. Five μg of pTR167-Nef-
(Chazal et al., 2001; Srinivasakumar et al., 1997) was used in
each case. Five μg of envelope expression vector and 2.5 μg
of Nef or 2.5 μg of pCMV-EGFP (Clontech) expression
vector were used as described in the figure legends. Each
plasmid was added to the cellular monolayer in the presence
of 0.5 mg/ml DEAE-dextran in a Tris-buffered saline solution
(TS). The cells were incubated at room temperature for 15
min and then at 37 °C for 45 min. The DNA containing
solution was washed off and the cells were then incubated
with 20% glycerol in TS for 70 s. The glycerol solution was
washed off and replaced with warmed IMDM+10% BCS and
0.1 mM chloroquine for 4 h. The chloroquine containing
media was aspirated and the cells were washed twice with TS.
IMDM+10% BCS and gentamicin (50 μg/ml) was added to
each plate. Three days later, the media was collected,
centrifuged to removed cellular debris, and used to infect
HeLa-CD4-CCR5 cells.
Hygromycin resistance infectivity assay
HeLa-CD4 or HeLa-CD4-CCR5 cells (2×105) were plated
in six well plates 24 h prior to infection. One hundred or ten μl
of transfected B41.4 supernatant, as indicated in the figure
legends, and 900 or 990 μl IMDM, respectively, containing
8 μg/ml DEAE-dextran were added to each well. The vector
containing media was allowed to incubate with the cells for 6 h,
after which time media was removed and replaced with IMDM
+10% BCS. Forty-eight hours later, the media was removed
and replaced with IMDM+10% BCS, hygromycin (200 μg/ml)
and gentamicin (50 μl/ml), which was changed every 2 days.
After 10 days under selection, the cells were washed twice with
PBS, stained with crystal violet, and washed under gently
35K. Olivieri et al. / Virology 358 (2007) 23–38running tap water. Colonies were manually counted after the
inverted plates had air-dried.
Titration of entry inhibitors against pseudotyped HIV-1 vectors
Infections were done as described above with the following
modifications. Prior to each infection, each inhibitor was diluted
to the concentrations described in the figures in IMDM+10%
BCS, 8 μg/ml DEAE-dextran and gentamicin (50 μl/ml). Nine
hundred μl of each inhibitor at each concentration was placed
on the cells and 100 μl of infectious supernatant was added.
Virus and inhibitor were incubated with the target cells for 24 h
at 37 °C. After which time, the inhibitor and virus containing
media was aspirated and replaced with 2 ml IMDM+10% BCS.
The selection and enumeration of colonies were carried out as
described above.
Determination of the kinetics of infection
Infections were initiated as described above, but at 0.25, 0.5,
1, 3, 6, and 12 h following the beginning of incubation at 37 °C,
the infectious supernatant was removed and replaced with
IMDM+10% BCS, gentamicin (50 μg/ml) and T-20 (1.8 μg/
ml). Selection and colony enumeration were done as described
above.
Analysis of titration of entry inhibitors and kinetics of infection
The GraphPad Prism software package was used to determine
the 50% inhibitory dose (IC50) for each entry inhibitor and the
time to 50% infectivity. This point was determined using variable
slope non-linear regression analysis with the fractional infectivity
values (y-axis values) constrained to be between 1 and 0.
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